Skip to content

Study · Animal study (in vivo) · rat · 2003

2 results

Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII.

Benoit SC, Sheldon RJ, Air EL, Messerschmidt P, Wilmer KA, Hodge KM, Jones MB, Eckstein DM, McOsker CC, Woods SC, Seeley RJ

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity1 May 2003Cited by 12 (Europe PMC)

PMID12704398 (opens in a new tab)DOI10.1038/sj.ijo.0802280 (opens in a new tab)PepBankPUB-12704398
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rats, chronic MTII from osmotic minipumps produced a conditioned taste aversion, with rats preferring the neutral flavor; saline rats showed no preference.

    In plain wordsIn rats, long-term melanotan II made rats avoid the flavor paired with it, unlike saline-treated rats.

    Peptide
    Melanotan II
    Outcome
    IncreaseConditioned taste aversion
    Study

    ratn: not reported in source

    Conditioned taste aversion test with osmotic minipumps
    Comparator
    Saline minipump
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · osmotic minipump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    By contrast, rats in both the LiCl and MTII minipump groups significantly preferred the neutral flavor, indicating the development of a CTA.
    2 context sentences
    Summary · context
    Rats with saline minipumps exhibited no preference for either flavor.
    Summary · context
    To accomplish this, we paired implantation of lithium chloride (LiCl)-, MTII- or saline-containing osmotic minipumps with a constantly available novel flavor. After 7 days, rats received a choice test between the minipump-paired flavor and a previously available neutral flavor.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, conditioned taste aversion from MTII was more resistant to extinction than that produced by LiCl.

    In plain wordsIn rats, the flavor avoidance caused by melanotan II took longer to fade than the avoidance caused by lithium chloride.

    Peptide
    Melanotan II
    Outcome
    IncreaseResistance of MTII conditioned taste aversion to extinction
    Study

    ratn: not reported in source

    Conditioned taste aversion test with osmotic minipumps
    Comparator
    Lithium chloride (LiCl)
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · osmotic minipump · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Additionally, CTA produced by administration of MTII was found to be more resistant to extinction than that produced by LiCl.
    1 context sentence
    Summary · context
    To accomplish this, we paired implantation of lithium chloride (LiCl)-, MTII- or saline-containing osmotic minipumps with a constantly available novel flavor. After 7 days, rats received a choice test between the minipump-paired flavor and a previously available neutral flavor.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.